Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
about
Uterine sarcoma - current perspectives.New targets and therapies for gastrointestinal stromal tumors.Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.
P2860
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Clinical Benefit in Response t ...... th a Common CDKN2A Alteration.
@ast
Clinical Benefit in Response t ...... th a Common CDKN2A Alteration.
@en
type
label
Clinical Benefit in Response t ...... th a Common CDKN2A Alteration.
@ast
Clinical Benefit in Response t ...... th a Common CDKN2A Alteration.
@en
prefLabel
Clinical Benefit in Response t ...... th a Common CDKN2A Alteration.
@ast
Clinical Benefit in Response t ...... th a Common CDKN2A Alteration.
@en
P2093
P2860
P1433
P1476
Clinical Benefit in Response t ...... th a Common CDKN2A Alteration.
@en
P2093
Alexa B Schrock
Garrett M Frampton
Jeffrey S Ross
Jennifer Long
Julia A Elvin
Lauren Shelley
Laurie M Gay
Philip J Stephens
Richard Frank
P2860
P304
P356
10.1634/THEONCOLOGIST.2016-0310
P577
2017-03-10T00:00:00Z